Skip to main content
Premium Trial:

Request an Annual Quote

Wellcome Trust Case Control Consortium to Use Illumina BeadChips to Study 90K Samples

NEW YORK (GenomeWeb News) – Scientists in the Wellcome Trust Case Control Consortium 2 will use Illumina’s Infinium HD BeadChips in a large-scale project to identify genetic variants linked to a number of diseases, including multiple sclerosis, schizophrenia, and asthma, the company said today.
Illumina said the Wellcome Trust-funded initiative, which comprises the WTCCC2 and 12 independent consortia, will analyze 90,000 DNA samples for both SNPs and copy number variants.
The company said that the proposed series of genome-wide association studies is “collectively the world's largest genetic research initiative conducted to date.”
In addition to the 90,000 samples collected from study participants, the researchers will collect 6,000 control samples that will be analyzed using Illumina's Infinium HD Human1M-Duo BeadChip.
Researchers involved in the initiative expect to generate 120 billion pieces of genetic data over the coming two years, the company said.
Financial terms of the agreement were not released.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.